Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen B Fox

Showing results (131-140 of 258) with videos related to

Pageof 26
Sort By:
Pathology|May 26, 2022
Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNARainier Arnolda, Kerryn Howlett, Timmy Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancerDaniele Generali, Stephen B Fox, Alfredo Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancerDaniele Generali, Alfredo Berruti, Maria P Brizzi, et al.
Breast Cancer Research and Treatment|September 21, 2005
Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysisSteven Van Laere, Ilse Van der Auwera, Gert G Van den Eynden, et al.
Pathology|October 12, 2021
ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performanceOwen W J Prall, Judy Browning, Violeta Nastevski, et al.
Breast Cancer Research and Treatment|June 9, 2012
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization ProgramMichael Bilous, Adrienne L Morey, Jane E Armes, et al.
Endocrine-Related Cancer|September 7, 2006
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancerDaniele Generali, Stephen B Fox, Alfredo Berruti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancerDaniele Generali, Francesca M Buffa, Alfredo Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patientsDaniele Generali, Gaynor Bates, Alfredo Berruti, et al.
Cancers|September 28, 2021
Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical RelevanceVeronica Zelli, Valentina Silvestri, Virginia Valentini, et al.
Pageof 26

Showing results (131-140 of 258) with videos related to

Sort By:
Pageof 26
Pathology|May 26, 2022
Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNARainier Arnolda, Kerryn Howlett, Timmy Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancerDaniele Generali, Stephen B Fox, Alfredo Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancerDaniele Generali, Alfredo Berruti, Maria P Brizzi, et al.
Breast Cancer Research and Treatment|September 21, 2005
Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysisSteven Van Laere, Ilse Van der Auwera, Gert G Van den Eynden, et al.
Pathology|October 12, 2021
ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performanceOwen W J Prall, Judy Browning, Violeta Nastevski, et al.
Breast Cancer Research and Treatment|June 9, 2012
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization ProgramMichael Bilous, Adrienne L Morey, Jane E Armes, et al.
Endocrine-Related Cancer|September 7, 2006
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancerDaniele Generali, Stephen B Fox, Alfredo Berruti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancerDaniele Generali, Francesca M Buffa, Alfredo Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patientsDaniele Generali, Gaynor Bates, Alfredo Berruti, et al.
Cancers|September 28, 2021
Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical RelevanceVeronica Zelli, Valentina Silvestri, Virginia Valentini, et al.
Pageof 26